Canada's Drug Agency Estimates Wegovy Costs $5,000 Annually

Official Government Costing Analysis

The $5,000 annual figure represents Canada's Drug Agency's calculation for Wegovy at its recommended maintenance dose. This official government estimate provides a standardized baseline for cost assessments across provincial drug programs and private insurers.

The Drug Agency's analysis likely factors in the 2.4 mg weekly maintenance dose that patients typically reach after completing the initial dose escalation schedule. Current monthly pricing for Wegovy ranges from $400 to $570 CAD at Canadian pharmacies, depending on dose strength and pharmacy location.

Provincial Coverage Implications

The official $5,000 annual cost estimate will inform provincial drug plan decisions about potential coverage for Wegovy. Provincial health ministries use these Drug Agency assessments when evaluating whether to add medications to their formularies and determining appropriate patient contribution levels.

The standardized costing also enables provinces to compare Wegovy's annual expense against other medications in their drug budgets. Several provinces are currently reviewing coverage options for GLP-1 medications through their respective drug review processes.

Comparison with Other GLP-1 Medications

The $5,000 annual estimate for Wegovy can be compared against other GLP-1 medications available in Canada. Ozempic typically costs between $300-400 monthly, while Mounjaro pricing varies by dose strength.

The Drug Agency's official costing provides a benchmark that private insurers and employers can reference when designing their drug benefit programs. This standardized assessment helps create consistency across different coverage programs nationwide.

Generic Competition Timeline

Health Canada is currently reviewing nine generic semaglutide applications, with approvals expected between May and September 2026. Generic versions could reduce annual costs significantly, though the Drug Agency has not yet published cost estimates for generic alternatives.

The $5,000 brand-name annual cost establishes a baseline that generic manufacturers will likely undercut substantially. Generic drugs typically enter the Canadian market at 65-85% below brand-name pricing, suggesting potential annual costs of $750-1,750 for generic semaglutide.

Patients can track generic approval progress using our generic semaglutide tracker and check current coverage options through our insurance coverage checker.

Cost-Effectiveness Considerations

The Drug Agency's $5,000 annual figure will factor into health economic evaluations that provinces conduct when assessing new drug coverage. These analyses compare medication costs against potential healthcare savings and treatment outcomes.

Provincial drug programs typically require cost-effectiveness demonstrations before adding expensive medications to their formularies. The official $5,000 estimate provides a standardized starting point for these economic assessments across all provinces.

For additional information about GLP-1 medication costs and coverage, visit our comprehensive FAQ section.